Rhinomed Completes Successful Capital Raise And Cornerstone Investment
Australian respiratory technology company Rhinomed Limited (ASX:RNO) is pleased to advise that it has undertaken a AUD$2.1million private placement. The placement was made to two US based sophisticated investor groups under ASX Listing rule 7.1 and the company’s current 15% capacity.